Introduction: Pulmonary sarcomatoid carcinoma (PSC) is a very rare subtype of non-small-cell lung cancer (NSCLC). It is frequently diagnosed in the advanced stage and is resistant to conventional chemotherapeutics. Due to the unique nature and rarity, we evaluated the epidemiological, clinicopathological, and survival data of PSC patients treated at our centre. Patients and Methods: We retrospectively collected demographic and clinical data of 67 PSC patients from a single tertiary referral hospital, between the 2000 and 2018. Univariate and multivariate analyses were performed to determine the risk factors affecting survival. Results: The median age was 61 years, and the percentage of male was 74.6%. Most of the patients had a smoking history (76.9%). The most common PSC subtype was pleomorphic carcinoma (46.3%). The median overall survival (OS) was 55.4 months, and the 5-year OS rate was 47.5%. Advanced stage, T4 tumour, and positive lymph node involvement were associated with poor OS (p < 0.05). The patients with negative epithelial markers had poorer prognosis (p = 0.027) and had more frequently stage IV disease (p = 0.016). Surgical treatment and stage IV disease were determined to be independent prognostic factors. Conclusion: PSC is an extremely rare and aggressive variant of NSCLC. Positive epithelial markers may have favourable prognostic significance in PSC. Resection of the tumour with a negative surgical margin is crucial for better survival. The prognosis of the disease is very poor in the metastatic stage.

1.
Barta
JA
,
Powell
CA
,
Wisnivesky
JP
.
Global epidemiology of lung cancer
.
Ann Glob Health
.
2019
;
85
. http://dx.doi.org/10.5334/aogh.2419.
2.
Steuer
CE
,
Behera
M
,
Liu
Y
,
Fu
C
,
Gillespie
TW
,
Saba
NF
,
.
Pulmonary sarcomatoid carcinoma: an analysis of the national cancer data base
.
Clin Lung Cancer
.
2017
;
18
:
286
92
.
3.
Yendamuri
S
,
Caty
L
,
Pine
M
,
Adem
S
,
Bogner
P
,
Miller
A
,
.
Outcomes of sarcomatoid carcinoma of the lung: a surveillance, epidemiology, and end results database analysis
.
Surgery
.
2012
;
152
:
397
402
.
4.
Travis
WD
,
Brambilla
E
,
Nicholson
AG
,
Yatabe
Y
,
Austin
JHM
,
Beasley
MB
,
.
The 2015 world health organization classification of lung tumours: impact of genetic, clinical and radiologic advances since the 2004 classification
.
J Thorac Oncol
.
2015
;
10
:
1243
60
.
5.
Lin
Y
,
Yang
H
,
Cai
Q
,
Wang
D
,
Rao
H
,
Lin
S
,
.
Characteristics and prognostic analysis of 69 patients with pulmonary sarcomatoid carcinoma
.
Am J Clin Oncol
.
2016
;
39
:
215
22
.
6.
Karim
NA
,
Schuster
J
,
Eldessouki
I
,
Gaber
O
,
Namad
T
,
Wang
J
,
.
Pulmonary sarcomatoid carcinoma: University of Cincinnati experience
.
Oncotarget
.
2018
;
9
:
4102
8
.
7.
Sim
JK
,
Chung
SM
,
Choi
JH
,
Oh
JY
,
Lee
SH
,
Kim
JH
,
.
Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma
.
Korean J Intern Med
.
2018
;
33
:
737
44
.
8.
Weissferdt
A
,
Kalhor
N
,
Correa
AM
,
Moran
CA
.
“Sarcomatoid” carcinomas of the lung: a clinicopathological study of 86 cases with a new perspective on tumour classification
.
Hum Pathol
.
2017
;
63
:
14
26
.
9.
Rossi
G
,
Cavazza
A
,
Sturm
N
,
Migaldi
M
,
Facciolongo
N
,
Longo
L
,
.
Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases
.
Am J Surg Pathol
.
2003
;
27
:
311
24
.
10.
Forest
F
,
Yvorel
V
,
Karpathiou
G
,
Stachowicz
ML
,
Vergnon
JM
,
Fournel
P
,
.
Histomolecular profiling of pleomorphic, spindle cell, and giant cell carcinoma of the lung for targeted therapies
.
Hum Pathol
.
2016
;
49
:
99
106
.
11.
Italiano
A
,
Cortot
AB
,
Ilie
M
,
Martel-Planche
G
,
Fabas
T
,
Pop
D
,
.
EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy
.
Int J Cancer
.
2009
;
125
:
2479
82
.
12.
Holst
VA
,
Finkelstein
S
,
Colby
TV
,
Myers
JL
,
Yousem
SA
.
p53 and K-ras mutational genotyping in pulmonary carcinosarcoma, spindle cell carcinoma, and pulmonary blastoma: implications for histogenesis
.
Am J Surg Pathol
.
1997
;
21
:
801
11
.
13.
Nakatani
Y
,
Miyagi
Y
,
Takemura
T
,
Oka
T
,
Yokoi
T
,
Takagi
M
,
.
Aberrant nuclear/cytoplasmic localization and gene mutation of beta-catenin in classic pulmonary blastoma: beta-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastomatoid variant of carcinosarcoma
.
Am J Surg Pathol
.
2004
;
28
:
921
7
.
14.
Weissferdt
A
,
Kalhor
N
,
Rodriguez Canales
J
,
Fujimoto
J
,
Wistuba
II
,
Moran
CA
.
Spindle cell and pleomorphic (“sarcomatoid”) carcinomas of the lung: an immunohistochemical analysis of 86 cases
.
Hum Pathol
.
2017
;
59
:
1
9
.
15.
Wang
T
,
Chen
X
,
Qiao
W
,
Kong
L
,
Sun
D
,
Li
Z
.
Transcription factor E2F1 promotes EMT by regulating ZEB2 in small cell lung cancer
.
BMC cancer
.
2017
;
17
:
719
.
16.
Vieira
T
,
Girard
N
,
Ung
M
,
Monnet
I
,
Cazes
A
,
Bonnette
P
,
.
Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma
.
J Thorac Oncol
.
2013
;
8
:
1574
7
.
17.
Maneenil
K
,
Xue
Z
,
Liu
M
,
Boland
J
,
Wu
F
,
Stoddard
SM
,
.
Sarcomatoid carcinoma of the lung: the Mayo Clinic experience in 127 Patients
.
Clin Lung Cancer
.
2018
;
19
:
e323
e33
.
18.
Gu
L
,
Xu
Y
,
Chen
Z
,
Pan
Y
,
Lu
S
.
Clinical analysis of 95 cases of pulmonary sarcomatoid carcinoma
.
Biomed Pharmacother
.
2015
;
76
:
134
40
.
19.
Huang
SY
,
Shen
SJ
,
Li
XY
.
Pulmonary sarcomatoid carcinoma: a clinicopathologic study and prognostic analysis of 51 cases
.
World J Surg Oncol
.
2013
;
11
:
252
.
20.
Tong
JH
,
Yeung
SF
,
Chan
AW
,
Chung
LY
,
Chau
SL
,
Lung
RW
,
.
MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis
.
Clin Cancer Res
.
2016
;
22
:
3048
56
.
21.
Velcheti
V
,
Rimm
DL
,
Schalper
KA
.
Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1)
.
J Thorac Oncol
.
2013
;
8
:
803
5
.
22.
Kim
S
,
Kim
MY
,
Koh
J
,
Go
H
,
Lee
DS
,
Jeon
YK
,
.
Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: comparison of sarcomatous and carcinomatous areas
.
Eur J Cancer
.
2015
;
51
:
2698
707
.
23.
Detterbeck
FC
,
Boffa
DJ
,
Kim
AW
,
Tanoue
LT
.
The eighth edition lung cancer stage classification
.
Chest
.
2017
;
151
:
193
203
.
24.
Eisenhauer
EA
,
Therasse
P
,
Bogaerts
J
,
Schwartz
LH
,
Sargent
D
,
Ford
R
,
.
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
.
Eur J Cancer
.
2009
;
45
:
228
47
.
25.
Ceppi
M
,
Munnia
A
,
Cellai
F
,
Bruzzone
M
,
Peluso
MEM
.
Linking the generation of DNA adducts to lung cancer
.
Toxicology
.
2017
;
390
:
160
6
.
26.
Fishback
NF
,
Travis
WD
,
Moran
CA
,
Guinee
DG
Jr
,
McCarthy
WF
,
Koss
MN
.
Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases
.
Cancer
.
1994
;
73
:
2936
45
.
27.
Lim
W
,
Ridge
CA
,
Nicholson
AG
,
Mirsadraee
S
.
The 8(th) lung cancer TNM classification and clinical staging system: review of the changes and clinical implications
.
Quant Imaging Med Surg
.
2018
;
8
:
709
18
.
28.
Kim
JH
,
Kim
HS
,
Kim
BJ
,
Han
B
,
Choi
DR
,
Kwon
JH
.
Prognostic impact of TTF-1 expression in nonsquamous non-small-cell lung cancer: a meta-analysis
.
J Cancer
.
2018
;
9
:
4279
86
.
29.
Qian
HH
,
Xu
TS
,
Cai
XQ
,
Ji
TL
,
Guo
HX
.
Prognostic value of TTF-1 expression in patients with non-small cell lung cancer: a meta-analysis
.
Clin Chim Acta
.
2015
;
451
:
208
14
.
30.
Ma
Y
,
Fan
M
,
Dai
L
,
Kang
X
,
Liu
Y
,
Sun
Y
,
.
Expression of p63 and CK5/6 in early-stage lung squamous cell carcinoma is not only an early diagnostic indicator but also correlates with a good prognosis
.
Thorac Cancer
.
2015
;
6
:
288
95
.
31.
Liu
J
,
Hu
G
,
Chen
D
,
Gong
AY
,
Soori
GS
,
Dobleman
TJ
,
.
Suppression of SCARA5 by Snail1 is essential for EMT-associated cell migration of A549 cells
.
Oncogenesis
.
2013
;
2
:
e73
.
32.
Ghulam
J
,
Stuerken
C
,
Wicklein
D
,
Pries
R
,
Wollenberg
B
,
Schumacher
U
.
Immunohistochemical analysis of transcription factors and Markers of Epithelial-Mesenchymal Transition (EMT) in human tumours
.
Anticancer Res
.
2019
;
39
:
5437
48
.
33.
Baquero
P
,
Jiménez-Mora
E
,
Santos
A
,
Lasa
M
,
Chiloeches
A
.
TGFβ induces epithelial-mesenchymal transition of thyroid cancer cells by both the BRAF/MEK/ERK and Src/FAK pathways
.
Mol Carcinog
.
2016
;
55
:
1639
54
.
34.
Wang
Z
,
Qu
L
,
Deng
B
,
Sun
X
,
Wu
S
,
Liao
J
,
.
STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling
.
Sci Rep
.
2016
;
6
:
33205
.
35.
Roesel
C
,
Terjung
S
,
Weinreich
G
,
Hager
T
,
Chalvatzoulis
E
,
Metzenmacher
M
,
.
Sarcomatoid carcinoma of the lung: a rare histological subtype of non-small cell lung cancer with a poor prognosis even at earlier tumour stages
.
Interact Cardiovasc Thorac Surg
.
2017
;
24
:
407
13
.
36.
Yuki
T
,
Sakuma
T
,
Ohbayashi
C
,
Yoshimura
M
,
Tsubota
N
,
Okita
Y
,
.
Pleomorphic carcinoma of the lung: a surgical outcome
.
J Thorac Cardiovasc Surg
.
2007
;
134
:
399
404
.
37.
Chang
YL
,
Wu
CT
,
Shih
JY
,
Lee
YC
.
EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy
.
Ann Surg Oncol
.
2011
;
18
:
2952
60
.
You do not currently have access to this content.